Project Grant R41DK115303

SIMPLEPATH IIB: Pre-Clinical Development of Cannabinoid Analogs Exozymes (California) Inc., operating as Invizyne Technologies Inc., received a $1,034,289 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) awarded July 1, 2026, with completion targeted for June 30, 2028. The award funds pre-clinical development of SIMPLEPATH IIB, a cell-free biomanufacturing platform utilizing a seven-enzyme system to...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

Grant Award Summary Angiotensin Therapeutics Inc. received a $591,488 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with completion targeted for August 31, 2026. The award funds preclinical research and development of AGT001, a bioengineered soluble Angiotensin-Converting Enzyme 2 (ACE2) therapeutic designed to treat...

Federal Project Grant Award Summary Regennova, Inc. received a $349,325 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective August 1, 2025, through July 31, 2027. The company is developing a novel oral therapeutic agent targeting the arginine-polyamine metabolic pathway as a treatment for autosomal dominant polycystic kidney disease (ADPKD), a...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $377,986 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Northern Colorado. The grant funds a 3-year research project to evaluate the therapeutic effects of the non-psychoactive cannabinoids cannabigerol (CBG) with or without cannabidiol (CBD) in alleviating the symptoms of diet-induced non-alcoholic fatty liver disease (NAFLD) and...

Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pennsylvania a $2.41 million Project Grant on September 9, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct the MONACO Clinical Trial. This five-year research initiative, scheduled for completion by May 31, 2030, will investigate nephrotoxicity markers in patients receiving combined antibiotic therapy with vancomycin and...

Regulonix LLC was awarded a $1,258,410 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to support research under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). Through this one-year award ending August 31, 2022, Regulonix will partner with the University of Arizona to characterize inhibitors of the neuropilin-1 (NRP-1) receptor for potential...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

Grant Award Summary SNC Therapeutics, Inc. received a $700,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 25, 2025 through July 24, 2026. The award funds development and research of rapamycin-loaded polymersomes (RPS), a tolerogenic nanotherapy designed to delay or prevent Type 1 Diabetes (T1D) onset in susceptible populations....